Peregrine Pharmaceuticals, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementPeregrine Pharmaceuticals Inc • December 29th, 2010 • In vitro & in vivo diagnostic substances • Colorado
Peregrine Pharmaceuticals, Inc. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC, a Delaware limited liability company (“MLV”), as follows:
